Abstract
An innovative approach, named associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), has made possible a marked increase in future liver remnant (FLR) over a short period of time, and has challenged the concept of unresectability. To date, ALPPS has been employed for a variety of primary and metastatic liver tumors from many centers across the world. Many technical variations of ALPPS have been described. However, much controversy has surrounded this procedure, and many problems remain to be solved, such as the reasons for rapid hypertrophy, the technical feasibility, safety and long-term oncologic outcomes, and the result compared with the conventional two-stage hepatectomy. These aspects are needed to be evaluated further in large-scale studies. We believe that the ALPPS procedure will has much room for further development. Key words: Liver neoplasms; Associating liver partition and portal vein ligation for staged hepatectomy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
